Identifying epitopes of HIV-1 that induce protective antibodies

During the past 20 years, the pendulum of opinion in the HIV-1 vaccine field has swung between two extremes, initially favouring the induction of antibodies only, and subsequently favouring the induction of cell-mediated immune responses only. At present, the consensus seems to be that induction of both humoral and cellular immunity by an HIV-1 vaccine will be required to achieve maximum protection. One obstacle to the development of an effective HIV-1 vaccine has been the difficulty in inducing broadly reactive, potent antibodies with protective functions. Defining epitopes and designing immunogens that will induce these antibodies is one of the main challenges that now confronts the HIV-1 vaccine field.

[1]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[2]  Abraham Pinter,et al.  Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.

[3]  N. Haigwood,et al.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. , 1996, Immunology letters.

[4]  W. Schleif,et al.  Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.

[5]  H. Sbai,et al.  Designing HIV-1 vaccines to reflect viral diversity and the global context of HIV/AIDS , 2001 .

[6]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[7]  P. Earl,et al.  The Human Immunodeficiency Virus Type 1 gp120 V2 Domain Mediates gp41-Independent Intersubunit Contacts , 2000, Journal of Virology.

[8]  S. Zolla-Pazner,et al.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.

[9]  H. Katinger,et al.  Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. , 2004, The Journal of infectious diseases.

[10]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[11]  S. Zolla-Pazner,et al.  Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. , 1994, Virology.

[12]  J. Sodroski,et al.  CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization , 1998, Journal of Virology.

[13]  Q. Sattentau,et al.  Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.

[14]  F. Valentine,et al.  Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide. , 1994, Journal of immunology.

[15]  Jamie K. Scott,et al.  Characterization of Murine Coronavirus Neutralization Epitopes with Phage-Displayed Peptides , 2000, Virology.

[16]  D. Bhattacharyya,et al.  Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. , 1996, AIDS research and human retroviruses.

[17]  A. Thitithanyanont,et al.  Effect of Amino Acid Substitution of the V3 and Bridging Sheet Residues in Human Immunodeficiency Virus Type 1 Subtype C gp120 on CCR5 Utilization , 2003, Journal of Virology.

[18]  C. Brooks,et al.  Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide. , 2000, Vaccine.

[19]  R. M. Hendry,et al.  Neutralization of primary HIV‐1 isolates by anti‐envelope monoclonal antibodies , 1995, AIDS.

[20]  H. Katinger,et al.  Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. , 1996, The Journal of general virology.

[21]  W. Irving,et al.  Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. , 2000, Virology.

[22]  H. Liao,et al.  Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope , 2001, Journal of Virology.

[23]  M. Parmentier,et al.  Importance of basic residues and quaternary structure in the function of MIP-1 beta: CCR5 binding and cell surface sugar interactions. , 2001, Biochemistry.

[24]  Joseph Sodroski,et al.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. , 2002, AIDS research and human retroviruses.

[25]  Michal Sharon,et al.  Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. , 2003, Structure.

[26]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[27]  S. Zolla-Pazner,et al.  Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M , 2000, Journal of Virology.

[28]  P. Berman,et al.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.

[29]  S. Zolla-Pazner,et al.  Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. , 1997, International immunology.

[30]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[31]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[32]  E. Check.  AIDS Vaccines: Back to 'plan A' , 2003, Nature.

[33]  Willy Wriggers,et al.  Spanning the length scales of biomolecular simulation. , 2004, Structure.

[34]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[35]  C. Barbas,et al.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[37]  C. E. Parker,et al.  Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.

[38]  A. Pinter,et al.  Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. , 1998, Vaccine.

[39]  S. Zolla-Pazner,et al.  Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Sodroski,et al.  Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.

[41]  D. Burton,et al.  Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.

[42]  J. Sodroski,et al.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions , 1993, Journal of virology.

[43]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[44]  S. Zolla-Pazner,et al.  Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. , 1992, AIDS research and human retroviruses.

[45]  Jamie K. Scott,et al.  Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12 , 2001, Journal of Virology.

[46]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[47]  G. Nakamura,et al.  Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies , 1988, Journal of virology.

[48]  D. Ho,et al.  Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.

[49]  C. Barbas,et al.  Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. , 1996, AIDS research and human retroviruses.

[50]  S. Zolla-Pazner,et al.  Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120. , 2000, AIDS research and human retroviruses.

[51]  A J Langlois,et al.  HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. , 1986, Science.

[52]  S. Zolla-Pazner,et al.  Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. , 1998, AIDS research and human retroviruses.

[53]  P. Murphy,et al.  Determinants of HIV-1 Coreceptor Function on CC Chemokine Receptor 3 , 1997, The Journal of Biological Chemistry.

[54]  B. Mandel.  Neutralization of Animal Viruses , 1978, Advances in Virus Research.

[55]  A. Pinter,et al.  A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. , 1993, AIDS research and human retroviruses.

[56]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Zolla-Pazner,et al.  Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41 , 2000, Journal of Virology.

[58]  V. Tugarinov,et al.  NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. , 2000, Structure.

[59]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[60]  M. Girardi,et al.  The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma , 2001, Annals of the New York Academy of Sciences.

[61]  P. Kaleebu,et al.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization , 1996, Journal of virology.

[62]  W A Hendrickson,et al.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.

[63]  S. Zolla-Pazner,et al.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. , 1993, Journal of immunology.

[64]  S. Szu,et al.  Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. , 1995, The Journal of infectious diseases.

[65]  M. Youle,et al.  Restriction of sensitivity of HIV-1-antigen ELISA by serum anti-core antibodies. , 1988, AIDS.

[66]  A. Trkola,et al.  A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B , 1995, Journal of virology.

[67]  A. Trkola,et al.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.

[68]  E A Emini,et al.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.

[69]  J. Robinson,et al.  Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Dennis R. Burton,et al.  Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.

[71]  S. Zolla-Pazner,et al.  Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. , 1993, Virology.

[72]  M. Hilleman.  Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. , 2001, Vaccine.

[73]  C Leclerc,et al.  Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.

[74]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[75]  A. Pinter,et al.  V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[76]  E. Fenyö,et al.  Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. Binley,et al.  Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions , 2003, Journal of Virology.

[78]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[79]  Emmanuel G. Cormier,et al.  The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor , 2002, Journal of Virology.

[80]  J. Safrit,et al.  Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. , 1995, The Journal of infectious diseases.

[81]  B. Dodet.  Retroviruses of Human AIDS and Related Animal Diseases , 2000 .

[82]  R. Garry,et al.  A general model for the transmembrane proteins of HIV and other retroviruses. , 1989, AIDS research and human retroviruses.

[83]  Groen,et al.  Multivariate analysis of human immunodeficiency virus type 1 neutralization data , 1996, Journal of virology.

[84]  J. Mascola,et al.  The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region , 2001, Journal of Virology.

[85]  Jon Cohen.  Escape Artist Par Excellence , 2003, Science.

[86]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[87]  J. Sodroski,et al.  Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus , 2000, Journal of Virology.

[88]  D. Burton.  Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[89]  L. Mofenson,et al.  Human Immunodeficiency Virus (HIV) Type 1 Antibodies in Perinatal HIV-1 Infection: Association with Human HIV-1 Transmission, Infection, and Disease Progression , 2000 .

[90]  Jon Cohen.  HIV. Escape artist par excellence. , 2003, Science.

[91]  A J Langlois,et al.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[93]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[94]  A. Fauci,et al.  Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. , 1999, Journal of immunology.

[95]  S. Zolla-Pazner,et al.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.

[96]  Yuxian He,et al.  Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci1 , 2002, The Journal of Immunology.

[97]  L. Stamatatos,et al.  Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. , 1997, Virology.

[98]  E. Berger,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by sCD4-17b, a Single-Chain Chimeric Protein, Based on Sequential Interaction of gp120 with CD4 and Coreceptor , 2003, Journal of Virology.

[99]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[100]  S. Zolla-Pazner,et al.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.

[101]  Nga Nguyen,et al.  Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites , 2003, Journal of Virology.

[102]  H. Liao,et al.  Induction of Antibodies in Guinea Pigs and Rhesus Monkeys against the Human Immunodeficiency Virus Type 1 Envelope: Neutralization of Nonpathogenic and Pathogenic Primary Isolate Simian/Human Immunodeficiency Virus Strains , 2000, Journal of Virology.

[103]  J. Hoxie,et al.  A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[104]  A. Yonezawa,et al.  Replacement of the V3 Region of gp120 with SDF-1 Preserves the Infectivity of T-Cell Line-Tropic Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[105]  R. Snyderman,et al.  A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[106]  J. Robinson,et al.  Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. , 1991, AIDS.

[107]  J. Sodroski,et al.  Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein , 1997, Journal of virology.

[108]  Robyn L Stanfield,et al.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. , 2004, Structure.

[109]  H. Katinger,et al.  Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. , 2004, The Journal of infectious diseases.

[110]  Robyn L Stanfield,et al.  Contrasting IgG structures reveal extreme asymmetry and flexibility. , 2002, Journal of molecular biology.

[111]  J. Mascola,et al.  The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.

[112]  S. Zolla-Pazner,et al.  Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. Betts,et al.  Signature of optimal doping in Hall-effect measurements on a high-temperature superconductor , 2003, Nature.

[114]  J. Mascola,et al.  Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry , 1995, Journal of virology.

[115]  L. Stamatatos,et al.  Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.

[116]  S. Zolla-Pazner,et al.  Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4 Binding Domain of gp120 , 2001, Journal of Virology.

[117]  J. Goudsmit.  Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. , 1988, AIDS (London).

[118]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[119]  Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.

[120]  S. Zolla-Pazner,et al.  Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates , 2002, Journal of Virology.

[121]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[122]  D. Birx,et al.  Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. , 1995, AIDS research and human retroviruses.

[123]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[124]  H. Fleury,et al.  Study of the V3 Loop as a Target Epitope for Antibodies Involved in the Neutralization of Primary Isolates versus T-Cell-Line-Adapted Strains of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[125]  J. Mascola,et al.  Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. , 1996, AIDS research and human retroviruses.

[126]  L. Stamatatos,et al.  An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades , 1998, Journal of Virology.

[127]  S. Zolla-Pazner,et al.  Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. , 1990, Journal of immunology.

[128]  M. Steward,et al.  A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response , 1995, Journal of virology.

[129]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[130]  New hope for AIDS vaccine. , 2003, Lancet.

[131]  S. Zolla-Pazner,et al.  Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. , 1997, Journal of immunology.

[132]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[133]  L. Cavacini,et al.  Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. , 2004, AIDS research and human retroviruses.

[134]  C. Broder,et al.  UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins , 2009 .

[135]  S. Zolla-Pazner,et al.  Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV , 1999, Journal of Virology.

[136]  J. Hansen,et al.  Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization , 1990, Journal of virology.

[137]  B. Korber,et al.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.

[138]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.